Federal Register / Vol. 86, No. 164 / Friday, August 27, 2021 / Notices 48229 

[FR Doc. 2021–18485 Filed 8–26–21; 8:45 am] 

BILLING CODE 4150–28–C 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 


lotter on DSK11XQN23PROD with NOTICES1EN27AU21.084</GPH>

Appendix I: Statutory Requirement of Annual Report Components 

As amended by the above laws, the Social Security Act (the Act}-specl/lcal/y section 1890{b)(S){A)-

mandates that the entity report to Congress and the Secretary of the Department of Health and Human 

services (HHS) no later than March 1st of each year. 

The report must Include descriptions of: 

• how NQF has Implemented quality. and efficiency measurement Initiatives under the Act and 

coordinated these Initiatives with those Implemented by other payers; 

• NQF's recommendations with respect to an Integrated national strategy and priorities for 

healthcare performance measurement In all applicable settings; 

• NQF's performance of the duties required under Its contract with HHS (Appendix A}: 

• gaps In endorsed quallty and efficiency measures, Including measures that are within priority 

areas Identified by the Secretary. under HHS' national strategy, and where quality and efficiency 

measures are unavailable or Inadequate to Identify or address such gaps; 

• areas In which evidence Is lnsu/ftclent to support endorsement of measures In priority areas 

Identified by the National auallty Strategy, and where targeted research may address such gaps; 

• matters related to convening multlstakeholder groups to provide Input on: a) the selection of 

certain quality and efficiency measures, and b) national priorities fr,r Improvement In population 

health and In the delivery of healthcare services fr,t conslderl:Jtlon under the National Quality 

Strategy;.(Throughout This Report, the Relevant Statutory Language Appears In ltallc/1ed Text., 

n.d.) 

• an lteml1atlon of f/npncial tnfr,rmotlon fer the /lscol year ending September 30 of the preceding 

year, fnc/μdlng: (I) onnua/ revenues of the entity (Including ony government funding, private 

sector contributions, grontS, membership revenues, ond Investment revenue); {II) annuol 

expenses of the entity (lnc/ud/ng.grantS paid, benefits paid, salaries or other compensotlon, 

fundralslng expenses, ond overhead casts}; and (Ill) a breakdown of the amount awarded per 

contracted task order and the specific projects funded In each task order assigned to the entity; 

and 

• any updates or modifications of Internal po/le/es and procedures of the entity as they relate to 

the duties of the entity under this section, Including: {I) speclflcal/y Identifying any modifications 

to the disclosure of Interests and conflicts of Interests fr,r committees, work groups, task fetces, 

and advisory panels of the entity; and (II) lnfr,tmatlon on external stakeholder participation In 

the duties of the entity under this.section (Including complete rosters fer all committees, work 

groups, tosk forces, and advisory panels funded through government contracts, descriptions of 

relevant Interests and any conflicts of Interest fer members.of al/committees, work groups, task 

fr,rces, and advisory panels, and the total percentage by health care sector of all convened 

committees, work groups, task ferces, and advisory panels, 
48230 Federal Register / Vol. 86, No. 164 / Friday, August 27, 2021 / Notices 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; NIAID Clinical Trial 

Implementation Cooperative Agreement (U01 

Clinical Trial Required); Investigator Initiated 

Extended Clinical Trial (R01 Clinical Trial 

Required). 

Date: September 27, 2021. 

Time: 11:45 a.m. to 3:45 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3G56, 

Rockville, MD 20892 (Virtual Meeting). 

Contact Person: Poonam Tewary, Ph.D., 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activities, 

National Institute of Allergy and Infectious 

Diseases, National Institutes of Health, 5601 

Fishers Lane, Room 3G56, Rockville, MD 

20852, (301) 761–7219, tewaryp@

mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: August 23, 2021. 

Tyeshia Roberson-Curtis, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–18501 Filed 8–26–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Center for Advancing 

Translational Sciences; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the 

cooperative agreement applications, the 

disclosure of which would constitute a 

clearly unwarranted invasion of 

personal privacy. 

Name of Committee: National Center for 

Advancing Translational Sciences Special 

Emphasis Panel; RFA–TR–21–009: Screening 

for Conditions by Electronic Nose 

Technology (SCENT). 

Date: September 28, 2021. 

Time: 10:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate 

cooperative agreement applications. 

Place: National Center for Advancing 

Translational Sciences, National Institutes of 

Health, 6701 Democracy Boulevard, Room 

1078, Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Rahat (Rani) Khan, Ph.D., 

Scientific Review Officer, Office of Grants 

Management and Scientific Review, National 

Center for Advancing Translational Sciences, 

National Institutes of Health, 6701 

Democracy Boulevard, Room 1078, Bethesda, 

MD 20892, 301–894–7319, khanr2@

csr.nih.gov. 

Name of Committee: National Center for 

Advancing Translational Sciences Special 

Emphasis Panel; National Center for 

Advancing Translational Sciences Special 

Emphasis Panel. 

Date: September 30, 2021 

Time: 11:00 a.m. to 3:00 p.m. 

Agenda: To review and evaluate 

cooperative agreement applications. 

Place: National Center for Advancing 

Translational Sciences, National Institutes of 

Health, 6701 Democracy Boulevard, Room 

1078, Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Alumit Ishai, Ph.D., 

Scientific Review Officer, Office of Grants 

Management and Scientific Review, National 

Center for Advancing Translational Sciences, 

National Institutes of Health, 6701 

Democracy Boulevard, Suite 1000, Bethesda, 

MD 20892, 301–827–5819, alumit.ishai@

nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.859, Pharmacology, 

Physiology, and Biological Chemistry 

Research; 93.350, B—Cooperative 

Agreements; 93.859, Biomedical Research 

and Research Training, National Institutes of 

Health, HHS) 

Dated: August 23, 2021. 

David W. Freeman, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–18505 Filed 8–26–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Neurological 

Disorders and Stroke; Notice of Closed 

Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Neurological Sciences 

Training Initial Review Group; NST–1 Study 

Section. 

Date: September 20–21, 2021. 

Time: 9:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852, (Virtual 

Meeting). 

Contact Person: William C. Benzing, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, Division of Extramural Research, 

NINDS, NIH, NSC, 6001 Executive Blvd., 

Suite 3204, MSC 9529, Bethesda, MD 20892– 

9529, (301) 496–0660, benzingw@

mail.nih.gov. 

Name of Committee: National Institute of 

Neurological Disorders and Stroke Special 

Emphasis Panel; NIH BRAIN Initiative 

Advanced Postdoctoral Career Transition 

Award to Promote Diversity (K99/R00). 

Date: September 23, 2021. 

Time: 9:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852, (Virtual 

Meeting). 

Contact Person: Lataisia Cherie Jones, 

Ph.D., Scientific Review Officer, NINDS, 

Scientific Review Branch, 6001 Executive 

Blvd., Suite 3208, Rockville, MD 20852, 301– 

496–9223, lataisia.jones@nih.gov. 

Name of Committee: National Institute of 

Neurological Disorders and Stroke Special 

Emphasis Panel; HEAL Initiative: Pain 

Therapeutics Development [Small Molecules 

and Biologics]. 

Date: September 27, 2021. 

Time: 10:00 a.m. to 3:00 p.m.. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852, (Virtual 

Meeting). 

Contact Person: Shanta Rajaram, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, Division of Extramural Activities, 

NINDS/NIH, NSC, 6001 Executive Blvd., 

Suite 3208, MSC 9529, Bethesda, MD 20892, 

(301) 435–6033, rajarams@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.853, Clinical Research 

Related to Neurological Disorders; 93.854, 

Biological Basis Research in the 

Neurosciences, National Institutes of Health, 

HHS) 

Dated: August 23, 2021. 

Tyeshia M. Roberson-Curtis, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–18508 Filed 8–26–21; 8:45 am] 

BILLING CODE 4140–01–P 


lotter on DSK11XQN23PROD with NOTICES1